InvestorsHub Logo
Followers 830
Posts 119742
Boards Moderated 17
Alias Born 09/05/2002

Re: DewDiligence post# 2522

Monday, 08/07/2023 4:14:25 PM

Monday, August 07, 2023 4:14:25 PM

Post# of 2996
ENTA FY3Q23* financials—6/30/23_cash=$393M:

https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-reports-financial-results-its-fiscal-36

FY3Q23 royalty revenue was $18.9M.†

FY3Q23 R&D expenses were $43.0M, consistent with the quarterly run rate of ENTA’s updated FY2023 guidance of $165-175M.

FY3Q23 SG&A expenses were $12.6M, consistent with the quarterly run rate of ENTA’s updated FY2023 guidance of $50-55M.

†ENTA’s partial sale of Mavyret royalties took effect on 7/1/23, so it did not affect the FY3Q23 income statement.

*ENTA’s fiscal years end on September 30.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News